Does Lurbinectedin Cause Birth Defects?
Lurbinectedin (trade name Zepzelca), an alkylating agent used for metastatic small cell lung cancer, is embryotoxic and teratogenic in animal studies. In rats and rabbits, it causes embryo-fetal lethality, reduced fetal weight, and major malformations at doses far below human equivalents—starting at one-tenth the recommended human dose (0.6 mg/m² IV). Observed defects include anasarca, amniotic fluid loss, abdominal wall defects (e.g., exomphalos), and skeletal abnormalities like fused sternebrae, shortened ribs, and ossification delays.[1][2]
No human data on fetal development exists due to ethical limits, but its genotoxic mechanism—binding DNA and inhibiting transcription—disrupts rapidly dividing fetal cells, mirroring other alkylators like cyclophosphamide, which cause craniofacial, limb, and organ defects.[3]
Pregnancy Warnings and Recommendations
FDA labels it Pregnancy Category Not Assigned (pre-2015 system), with clear warnings against use in pregnancy. It impairs fertility in animals and is genotoxic, posing risks to gametes. Women of reproductive potential must use effective contraception during treatment and for 6 months after; males for 4 months. Verify pregnancy status before starting.[1][2]
Healthcare providers report it to the Zepzelca Pregnancy Exposure Registry (1-888-661-2836) if exposure occurs.[2]
How Does It Disrupt Fetal Development Mechanically?
Lurbinectedin covalently binds DNA minor grooves, blocking RNA polymerase II and causing double-strand breaks. In fetuses, this halts cell proliferation in organogenesis windows (weeks 3-8 gestation), leading to:
- Neural tube and CNS defects: From disrupted neuroblast division.
- Cardiovascular and limb anomalies: Impaired mesenchymal migration.
- Growth restriction: Reduced placental and fetal cell turnover.
Animal models show dose-dependent effects: maternal toxicity (weight loss, deaths) at higher exposures amplifies fetal harm.[1][3]
What If Exposed During Pregnancy?
Unintended exposure risks miscarriage, preterm birth, or congenital anomalies. No antidote exists; management is supportive. Counsel on termination options early, as risks peak in first trimester. Breastfeeding is contraindicated due to excretion in milk.[2]
Alternatives for Cancer Patients Who Are Pregnant
Switch to less embryotoxic options if possible:
- Small cell lung cancer: Topotecan or irinotecan (also risky but sometimes used post-first trimester); clinical trials exclude pregnant patients.
- Supportive care or radiation (shielded) for palliation.
Consult oncology and maternal-fetal medicine specialists; etoposide-based regimens have more pregnancy data but still carry 20-30% malformation risk.[4]
Related Regulatory and Trial Data
Phase 2 trials (e.g., NCT02454972) excluded pregnant subjects; postmarketing surveillance tracks exposures. EMA and FDA require risk evaluation/mitigation strategies (REMS) emphasizing contraception.[1][2]
Sources
[1]: FDA Zepzelca Label
[2]: Drugs.com - Lurbinectedin
[3]: PubChem - Lurbinectedin
[4]: ASCO Guidelines on Cancer in Pregnancy